Want to see LONA full AI Analyst Report?
Top Page
LeonaBio
(NASDAQ:LONA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$8.00
▼(-0.12% Downside)
Action:Reiterated
Date:08/27/26
Overall score is held down primarily by weak financial performance (pre-revenue, widening losses, and sustained cash burn), which raises ongoing financing/dilution risk despite low debt. Technical indicators are neutral-to-mixed and do not provide strong support. Corporate events add some upside via the Phase 3 milestone and potential capital inflow, but valuation signals remain constrained by negative earnings and no dividend yield.
Positive Factors
Low Financial Leverage
Very low leverage limits interest and solvency pressure while the company funds development. This provides greater financial flexibility than a debt-heavy biotechnology peer, although it does not offset the need for external capital.
Negative Factors
Pre-Revenue Business Model
The absence of revenue leaves LeonaBio dependent on clinical success and future commercialization to create an economic engine. Without product sales, there is no demonstrated operating leverage, margin base, or internally funded path to profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low leverage limits interest and solvency pressure while the company funds development. This provides greater financial flexibility than a debt-heavy biotechnology peer, although it does not offset the need for external capital.
Read all positive factors
LeonaBio (LONA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.56M
Dividend YieldN/A
Average Volume (3M)42.79K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS Growth-49.65%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-32.78
Shares Outstanding9,421,663
10 Day Avg. Volume26,926
30 Day Avg. Volume42,788
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.33Price Target Upside116.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.51
Revenue Forecast (FY)N/A
LeonaBio Business Overview & Revenue Model
Company Description
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegener...
LeonaBio Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -68.56M | -68.09M | 0.00 | 0.00 | 0.00 | -479.00K |
| EBITDA | -53.66M | -33.21M | -95.81M | -125.97M | -88.01M | -54.37M |
| Net Income | -141.46M | -105.61M | -96.94M | -117.67M | -95.64M | -54.85M |
Balance Sheet | ||||||
| Total Assets | 56.89M | 92.15M | 58.78M | 160.25M | 258.15M | 332.01M |
| Cash, Cash Equivalents and Short-Term Investments | 51.07M | 88.33M | 51.27M | 147.42M | 200.34M | 253.76M |
| Total Debt | 577.00K | 803.00K | 1.22M | 1.58M | 1.91M | 1.92M |
| Total Liabilities | 23.30M | 64.36M | 13.94M | 30.06M | 23.02M | 10.92M |
| Stockholders Equity | 33.59M | 27.79M | 44.84M | 130.19M | 235.14M | 321.08M |
Cash Flow | ||||||
| Free Cash Flow | -61.93M | -45.73M | -97.20M | -101.06M | -73.61M | -44.67M |
| Operating Cash Flow | -61.93M | -45.73M | -97.17M | -100.75M | -72.47M | -43.10M |
| Investing Cash Flow | -8.19M | -15.89M | 54.83M | 95.09M | 57.66M | -4.08M |
| Financing Cash Flow | 82.55M | 82.46M | 194.00K | 493.00K | 654.00K | 97.09M |
LeonaBio Technical Analysis
Positive
8.01
Price Trends
7.97
Positive
8.57
Negative
7.52
Positive
Market Momentum
-0.03
Negative
54.07
Neutral
30.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LONA, the sentiment is Positive. The current price of 8.01 is above the 20-day moving average (MA) of 7.81, above the 50-day MA of 7.97, and above the 200-day MA of 7.52, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 54.07 is Neutral, neither overbought nor oversold. The STOCH value of 30.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LONA.
LeonaBio Risk Analysis
LeonaBio disclosed 91 risk factors in its most recent earnings report. LeonaBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LeonaBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $22.78M | -0.52 | -165.71% | ― | ― | 77.68% | |
52 Neutral | $13.52M | -4.88 | -31.88% | ― | 10.41% | 40.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $22.73M | -1.61 | -207.47% | ― | ― | 38.55% | |
47 Neutral | $75.56M | -0.21 | -411.58% | ― | ― | -49.65% | |
38 Underperform | $17.49M | -0.62 | -126.02% | ― | ― | 78.51% |
* Healthcare Sector Average
LONA
LeonaBio
7.04
3.23
84.78%
CLRB
Cellectar Biosciences
2.37
-2.64
-52.70%
IMRN
Immuron
1.76
-0.16
-8.33%
COCP
Cocrystal Pharma
1.24
-0.22
-15.07%
BIVI
BioVie
1.97
0.06
3.14%
LeonaBio Corporate Events
Business Operations and StrategyPrivate Placements and Financing
LeonaBio Reaches Key Phase 3 Enrollment Milestone
Positive
Aug 26, 2026
On August 26, 2026, LeonaBio reported enrollment of the 500th patient in its Phase 3 ELAINE-3 trial evaluating lasofoxifene with abemaciclib in a hard-to-treat subset of metastatic breast cancer, marking a significant clinical milestone for its le...
Executive/Board ChangesShareholder Meetings
LeonaBio Shareholders Approve Directors, Auditor and Compensation
Positive
Jun 23, 2026
On June 22, 2026, LeonaBio held its 2026 Annual Meeting of Stockholders, with approximately 84.19% of eligible shares present or represented by proxy, establishing a quorum for business. Stockholders elected three Class III directors, Kelly A. Rom...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.